|
Back to Home » June 2020 News » Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China |
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China |
June 18, 2020
SUZHOU, China, June 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,...
Source URL: https://www.prnewswire.com:443/news-releases/innovent-announces-first-patient-dosed-in-a-phase-1b2-clinical-trial-of-ibi362-a-dual-glp-1-and-glucagon-receptor-agonist-in-china-301079213.html
|
|
|
|
